iiinova — where your digital self keeps evolving

Reposted by Bertrand Knebelmann

AFP News Agency @en.afp.com · 05/10/2026

🏅 The Nobel medicine prize was awarded Monday to US psychiatrist and neurologist Karl Deisseroth and his German colleagues Peter Hegemann and Georg Nagel for their work in the field of optogenetics. ➡️ u.afp.com/S9rA

03610

Reposted by Bertrand Knebelmann

Nephrology Journal Club @nephjc.bsky.social · 28/09/2026

Hey #NephJC 👋 Checkout the VA by @divyaveerssneph.bsky.social This week we're looking at steroid weaning strategies in adults with podocytopathies (MCD/FSGS). 💊Steroids: easy to start🟢 but hard to stop 🛑. #NephSky www.nephjc.com/news/starttrial

nephjc.com

START: The Visual Abstract — NephJC

Can steroid tapering be shorter after remission in adults with sensitive podocytopathy?

089

Reposted by Bertrand Knebelmann

ASN Publications @asnpublications.bsky.social · 16/09/2026

Aortic disease may deserve a larger role in discussions about autosomal dominant polycystic kidney disease. New research suggests ADPKD is independently associated with a significantly higher risk of aortic dissection and aneurysm. kidney.pub/KN1809-23 #ASNKidneyNews

052

Reposted by Bertrand Knebelmann

Kidney International @kidneyint.bsky.social · 09/10/2025

Mono-allelic pathogenic variants in JAG1 cause Autosomal Dominant Tubulo-interstitial Kidney Disease (ADTKD-JAG1) doi.org/10.1016/j.kint.2025.08.033 #ckd #chronickidneydisease #MedSky #NephSky @institutimagine.bsky.social @lafhf.bsky.social @nihrnewcastlebrc.bsky.social @ap-hp.bsky.social

083

Reposted by Bertrand Knebelmann

ISNkidneycare @theisn.org · 17/10/2025

📖 This weekend don't miss our @kidneyint.bsky.social #ISNFridaySelection: Artificial intelligence and perspective for rare genetic kidney diseases www.kidney-internati...

031

Reposted by Bertrand Knebelmann

Prasad Jallepalli, MD, PhD @prasad.bsky.social · 11/08/2025

I'm not sure how NIH recovers any shred of credibility when its Director makes such a ridiculous statement

74017

Reposted by Bertrand Knebelmann

ASN Publications @asnpublications.bsky.social · 19/05/2025

Real-world challenges in the use of tolvaptan for ADPKD lead to high discontinuation rates and dosage adjustments, underscoring the need for standardized and improved management strategies to enhance tolerability and adherence. bit.ly/KID0816 @shelliefravel.bsky.social #ASNKidney360

184

Reposted by Bertrand Knebelmann

American Journal of Hypertension @amjhypertension.bsky.social · 13/05/2025

Only moderate concordance between a cuffless (Aktiia) and home BP measurements Strong patient preference for cuffless > cuffed devices 🔗 academic.oup.com/ajh/article/... 🔓 #OpenAccess #free N = 37 study #COOLBP

065

Reposted by Bertrand Knebelmann

Atul Gawande @agawande.bsky.social · 13/05/2025

“What I do know is that my colleagues, many…like me, foreign scientists, are terrified of being detained or having their visa status revoked.” It’s 3 months since ICE put Kseniia Petrova in detention for a customs violation normally handled with a fine. www.nytimes.com/2025/05/13/o...

nytimes.com

Opinion | I Came to Study Aging. Now I’m Trapped in ICE Detention.

112562

Bertrand Knebelmann @knebel.bsky.social · 13/05/2025

#actualités-Necker; great talk from idris boudhabay

020

Bertrand Knebelmann @knebel.bsky.social · 13/02/2025

Very important fact ignored by FPE afficionados

010

Reposted by Bertrand Knebelmann

Simone Sanna-Cherchi 🧬 @genetickidneydoc.bsky.social · 29/01/2025

Great! That's reassuring! I was worried about a slowdown or even a move back to the other platform... #Nephsky is healthy!

061